Pluristem Therapeutics Inc (PSTI)

[zzaatt]

Biotech industry future glum says expert

Except for companies that are engaged in a new paradigm approach, such as Pluristem!

The principal difference between biotech and pharma is that biotech uses the new tools of molecular biology to find large-molecule ligands to bind to target proteins, while pharma uses the tools of medicinal chemistry to find small-molecule ligands.

Pluristem is doing neither of the above!! Pluristem's MSCs modality is precisely what is outside the "large molecule/small molecule" paradigm. My takeaway from the article is very positive: our approach is neither of the above, and that is what makes Pluristem very valuable, AND very desperately needed by BP (partnership or buyout for big bucks down the line).

From the same article:

Smarter pharmas and new biotechs will seek to exploit paradigms other than one protein: one disease. They will focus on altering processes and systems, often by re-engineering them altogether: programming cells to act as semi-autonomous agents within the body.

That's Pluristem!!! Be happy(b)!